SUVENPHAR

SUVEN PHARMACEUTICALS

Mid Cap BSE: 543064 NSE: SUVENPHAR
₹460.5
34.25 (8.04%)
As on 30 September, 2022 | 02:57

Suven Pharmaceuticals Share Price

Suven Pharmaceuticals Performance

Day Range

  • Low
  • High

52 Week Range

  • Low
  • High
  • Open Price
  • Previous Close
  • Volume

Start SIP in SUVEN PHARMACEUTICALS

Start SIP

Suven Pharmaceuticals Share Returns

  • Over 1 Month -1.75%
  • Over 3 Month -0.84%
  • Over 6 Month -25.86%
  • Over 1 Year -11.79%

Suven Pharmaceuticals Key Statistics

P/E Ratio 25.7
PEG Ratio 1.2
Market Cap Cr 11,723
Price to Book Ratio 7.7
EPS 21.4
Dividend 2.4
Relative Strength Index 50.97
Money Flow Index 40.48
MACD Signal -5.32
Average True Range 19.15

Suven Pharmaceuticals Investment Rating

  • Master Rating:
  • Suven Pharmaceuticals has an operating revenue of Rs. 1,395.22 Cr. on a trailing 12-month basis. An annual revenue growth of 38% is outstanding, Pre-tax margin of 47% is great, ROE of 29% is exceptional. The company has a reasonable debt to equity of 2%, which signals a healthy balance sheet. The stock from a technical standpoint is trading below to its key moving averages. It needs to take out these levels and stay above it to make any meaningful move. From an O'Neil Methodology perspective, the stock has an EPS Rank of 40 which is a POOR score indicating inconsistency in earnings, a RS Rating of 22 which is POOR indicating the underperformance as compared to other stocks, Buyer Demand at B+ which is evident from recent demand for the stock, Group Rank of 124 indicates it belongs to a poor industry group of Medical-Generic Drugs and a Master Score of C is fair but needs to improve. Institutional holding has remained stable in the last reported quarter. Overall, the stock has poor technical strength and poor fundamentals, there are superior stocks in the current market environment.

EPS Strength

Price Strength

Buyer Demand

Group Rank

Suven Pharmaceuticals Financials
IndicatorJun 2022Mar 2022Dec 2021Sep 2021Jun 2021Mar 2021
Oper Rev Qtr Cr 339364392301264259
Operating Expenses Qtr Cr 184206206179149165
Operating Profit Qtr Cr 15515818612211594
Depreciation Qtr Cr 111011998
Interest Qtr Cr 121122
Tax Qtr Cr 405547352822
Net Profit Qtr Cr 1142241371158164

Suven Pharmaceuticals Technicals

EMA & SMA

Current Price
460.5
34.25 (8.04%)
  • Bullish Moving Average
  • ___
  • 0
  • Bearish Moving Average
  • ___
  • 0
  • 20 Day
  • 455.31
  • 50 Day
  • 464.46
  • 100 Day
  • 476.67
  • 200 Day
  • 507.33
  • 20 Day
  • 465.18
  • 50 Day
  • 464.47
  • 100 Day
  • 473.57
  • 200 Day
  • 507.52

Suven Pharmaceuticals Resistance and Support

PIVOT
₹425.9
Resistance
First Resistance 433.3
Second Resistance 440.35
Third Resistance 447.75
RSI 50.97
MFI 40.48
MACD Single Line -5.32
MACD -8.86
Support
First Resistance 418.85
Second Resistance 411.45
Third Resistance 404.4

Suven Pharmaceuticals Delivery and Volume

Period NSE + BSE Volume Avg NSE + BSE Delivery Volume Avg NSE + BSE Delivery Volume %
Day 649,148 21,908,745 33.75
Week 380,582 20,684,653 54.35
1 Month 418,319 25,048,967 59.88
6 Month 280,577 15,827,343 56.41

Suven Pharmaceuticals Result Highlights

Suven Pharmaceuticals Synopsis

NSE-Medical-Generic Drugs

Suven Pharmaceutical is involved in the business activities of Manufacture of pharmaceuticals, medicinal chemical and botanical products. Company’s Total Operating Revenue is Rs. 1320.22 Cr. and Equity Capital is Rs. 25.46 Cr. for the Year ended 31/03/2022. Suven Pharmaceuticals Ltd. is a Public Limited Listed company incorporated on 06/11/2018 and has its registered office in the State of Telangana, India. Company’s Corporate Identification Number(CIN) is L24299TG2018PLC128171 and registration number is 128171.
Market Cap 11,723
Sales 1,395
Shares in Float 10.18
No of funds 149
Yield 0.65
Book Value 7.71
U/D Vol ratio 0.9
LTDebt / Equity 2
Alpha -0.03
Beta 0.69

Suven Pharmaceuticals

Owner NameJun-22Mar-22Dec-21Sep-21
Promoters 60%60%60%
Mutual Funds 6.32%5.91%5.24%
Foreign Portfolio Investors 8.49%8.56%8.25%
Financial Institutions/ Banks
Individual Investors 16.86%17.07%18.37%
Others 8.33%8.46%8.14%

Suven Pharmaceuticals Management

Name Designation
Mr. Venkateswarlu Jasti Managing Director
Ms. Deepanwita Chattopadhyay Independent Director
Dr. Jerry Jeyasingh Non Exe.Non Ind.Director
Mr. J V Ramudu Chairman, Non Ind & Non Exe Director
Mr. D G Prasad Independent Director
Dr. V Sambasiva Rao Independent Director

Suven Pharmaceuticals Forecast

Price Estimates

2,000(9.8%)
1,758(-3.5%)
1,590(-12.7%)

Other Analyst Rating

Suven Pharmaceuticals Corporate Action

Date Purpose Remarks
2022-08-08 Quarterly Results
2022-05-09 Audited Results & Interim Dividend
2022-02-08 Quarterly Results & Interim Dividend
2021-11-06 Quarterly Results
2021-08-13 Quarterly Results
Date Purpose Remarks
2022-09-12 INTERIM Rs.1.00 per share(100%)Interim Dividend
2022-09-12 SPECIAL Rs.5.00 per share(500%)Special Dividend
2022-05-17 INTERIM Re.1.00 per shaer (100%) Second Interim Dividend
2022-05-17 SPECIAL Rs.1.00 per share(100%)Special Dividend
2022-02-16 INTERIM Rs.1.00 per share(100%)Interim Dividend

Suven Pharmaceuticals MF Shareholding

Name Amount(cr)
UTI Flexi Cap Fund Regular Plan Growth 26503
L&T Emerging Businesses Fund Regular Growth 8395
PGIM India Flexi Cap Fund Regular Growth 7990
UTI Value Opportunities Fund Regular Plan Growth 6923
L&T Midcap Fund Growth 6674

Suven Pharmaceuticals FAQs

What is Share Price of Suven Pharmaceuticals ?

Suven Pharmaceuticals share price is ₹460 As on 30 September, 2022 | 02:43

What is the Market Cap of Suven Pharmaceuticals ?

The Market Cap of Suven Pharmaceuticals is ₹11722.7 Cr As on 30 September, 2022 | 02:43

What is the P/E ratio of Suven Pharmaceuticals ?

The P/E ratio of Suven Pharmaceuticals is 25.7 As on 30 September, 2022 | 02:43

What is the PB ratio of Suven Pharmaceuticals ?

The PB ratio of Suven Pharmaceuticals is 7.7 As on 30 September, 2022 | 02:43

Q1FY23